Overexpression of inactive tetherin delGPI mutant inhibits HIV-1 Vpu-mediated antagonism of endogenous tetherin. 2013

Mingyu Lv, and Jiawen Wang, and Yingzi Zhu, and Xiaodan Wang, and Tao Zuo, and Donglai Liu, and Jingyao Zhang, and Jiaxin Wu, and Haihong Zhang, and Wei Kong, and Xianghui Yu
National Engineering Laboratory for AIDS Vaccine, College of Life Science, Jilin University, Changchun, Jilin Province, People's Republic of China.

Tetherin/BST-2/CD317 inhibits HIV-1 release from infected cells, but the viral Vpu protein efficiently antagonizes this antiviral activity through direct interaction between the transmembrane (TM) domains of each protein. Here, we demonstrated that overexpression of an inactive tetherin delGPI mutant, the TM domain of which could competitively block Vpu targeting of endogenous tetherin, potently inhibited HIV-1 release from human tetherin-positive cells in both transient and stable expression conditions. These results also suggest that heterologous dimerization occurred between the delGPI mutant and endogenous tetherin. These findings suggest that blocking the Vpu/tetherin interface may be a novel therapeutic approach against HIV-1 release.

UI MeSH Term Description Entries
D008856 Microscopy, Fluorescence Microscopy of specimens stained with fluorescent dye (usually fluorescein isothiocyanate) or of naturally fluorescent materials, which emit light when exposed to ultraviolet or blue light. Immunofluorescence microscopy utilizes antibodies that are labeled with fluorescent dye. Fluorescence Microscopy,Immunofluorescence Microscopy,Microscopy, Immunofluorescence,Fluorescence Microscopies,Immunofluorescence Microscopies,Microscopies, Fluorescence,Microscopies, Immunofluorescence
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005240 Feasibility Studies Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project. Feasibility Study,Studies, Feasibility,Study, Feasibility
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014771 Virion The infective system of a virus, composed of the viral genome, a protein core, and a protein coat called a capsid, which may be naked or enclosed in a lipoprotein envelope called the peplos. Virus Particle,Viral Particle,Viral Particles,Particle, Viral,Particle, Virus,Particles, Viral,Particles, Virus,Virions,Virus Particles
D015202 Protein Engineering Procedures by which protein structure and function are changed or created in vitro by altering existing or synthesizing new structural genes that direct the synthesis of proteins with sought-after properties. Such procedures may include the design of MOLECULAR MODELS of proteins using COMPUTER GRAPHICS or other molecular modeling techniques; site-specific mutagenesis (MUTAGENESIS, SITE-SPECIFIC) of existing genes; and DIRECTED MOLECULAR EVOLUTION techniques to create new genes. Genetic Engineering of Proteins,Genetic Engineering, Protein,Proteins, Genetic Engineering,Engineering, Protein,Engineering, Protein Genetic,Protein Genetic Engineering
D015316 Genetic Therapy Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions. Gene Therapy,Somatic Gene Therapy,DNA Therapy,Gene Therapy, Somatic,Genetic Therapy, Gametic,Genetic Therapy, Somatic,Therapy, DNA,Therapy, Gene,Therapy, Somatic Gene,Gametic Genetic Therapies,Gametic Genetic Therapy,Genetic Therapies,Genetic Therapies, Gametic,Genetic Therapies, Somatic,Somatic Genetic Therapies,Somatic Genetic Therapy,Therapies, Gametic Genetic,Therapies, Genetic,Therapies, Somatic Genetic,Therapy, Gametic Genetic,Therapy, Genetic,Therapy, Somatic Genetic
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Mingyu Lv, and Jiawen Wang, and Yingzi Zhu, and Xiaodan Wang, and Tao Zuo, and Donglai Liu, and Jingyao Zhang, and Jiaxin Wu, and Haihong Zhang, and Wei Kong, and Xianghui Yu
January 2011, PloS one,
Mingyu Lv, and Jiawen Wang, and Yingzi Zhu, and Xiaodan Wang, and Tao Zuo, and Donglai Liu, and Jingyao Zhang, and Jiaxin Wu, and Haihong Zhang, and Wei Kong, and Xianghui Yu
March 2017, Journal of virology,
Mingyu Lv, and Jiawen Wang, and Yingzi Zhu, and Xiaodan Wang, and Tao Zuo, and Donglai Liu, and Jingyao Zhang, and Jiaxin Wu, and Haihong Zhang, and Wei Kong, and Xianghui Yu
June 2014, Journal of virology,
Mingyu Lv, and Jiawen Wang, and Yingzi Zhu, and Xiaodan Wang, and Tao Zuo, and Donglai Liu, and Jingyao Zhang, and Jiaxin Wu, and Haihong Zhang, and Wei Kong, and Xianghui Yu
January 2008, Nature,
Mingyu Lv, and Jiawen Wang, and Yingzi Zhu, and Xiaodan Wang, and Tao Zuo, and Donglai Liu, and Jingyao Zhang, and Jiaxin Wu, and Haihong Zhang, and Wei Kong, and Xianghui Yu
April 2014, Proceedings of the National Academy of Sciences of the United States of America,
Mingyu Lv, and Jiawen Wang, and Yingzi Zhu, and Xiaodan Wang, and Tao Zuo, and Donglai Liu, and Jingyao Zhang, and Jiaxin Wu, and Haihong Zhang, and Wei Kong, and Xianghui Yu
July 2015, Scientific reports,
Mingyu Lv, and Jiawen Wang, and Yingzi Zhu, and Xiaodan Wang, and Tao Zuo, and Donglai Liu, and Jingyao Zhang, and Jiaxin Wu, and Haihong Zhang, and Wei Kong, and Xianghui Yu
June 2012, Current HIV research,
Mingyu Lv, and Jiawen Wang, and Yingzi Zhu, and Xiaodan Wang, and Tao Zuo, and Donglai Liu, and Jingyao Zhang, and Jiaxin Wu, and Haihong Zhang, and Wei Kong, and Xianghui Yu
September 2023, Infectious medicine,
Mingyu Lv, and Jiawen Wang, and Yingzi Zhu, and Xiaodan Wang, and Tao Zuo, and Donglai Liu, and Jingyao Zhang, and Jiaxin Wu, and Haihong Zhang, and Wei Kong, and Xianghui Yu
September 2011, Virology,
Mingyu Lv, and Jiawen Wang, and Yingzi Zhu, and Xiaodan Wang, and Tao Zuo, and Donglai Liu, and Jingyao Zhang, and Jiaxin Wu, and Haihong Zhang, and Wei Kong, and Xianghui Yu
November 2016, Cell reports,
Copied contents to your clipboard!